Affiliations: [a] Iranian Blood Transfusion Organization, Research Centre, Tehran, Iran | [b] Department of Immunology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran | [c] Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran | [d] Iranian Blood Research and Fractionation Company, Research Centre, Tehran, Iran
Correspondence:
[*]
Corresponding author: Dr. A. Aghaie, Iranian Blood Transfusion Organization, Research Centre, Tehran, P.O. BOX 14665-1157, Iran. Tel.: +98 2188601501; Fax: +98 21 88601555; E-mail: [email protected].
Abstract: IVIG can be prepared from fractionation of normal human plasma and it is used as a therapeutic drug for treatment of various diseases. IVIG has been for some time the high-growth product within the plasma derived products, at both a global and a national country level. Fractionation was performed according to Cohn method with some modifications. Fraction II was first produced and then it was used for purification and virus inactivation steps. Two methods of virus inactivation (pasteurization at 60°C for 10 hours and solvent/detergent treatment with TnBP and Tween 80) were used and validated. A chromatography method (cation exchange chromatography on CM Sepharose FF) was also added to obtain high purity. The final product (in liquid and freeze dried formulation) meets European Pharmacopeias requirements. The amount of PKA and aggregates was beyond the acceptance limit. The intactness of the IVIG was also examined by circular dichroism (secondary and tertiary structure). It was stable after 6 months of storage. Since Iran market is completely dependant on importation of plasma derived products, it is important to develop such methods for production of IVIG to obtain regional demands.
Keywords: Intravenous immunoglobulin, fractionation, solvent/detergent, pasteurization, structural study
